Skip to main content
OpenTrials
Completed

NCT Number: NCT05855798

Ketamine and Magnesium in Erector Spinae Plane Block

In this study, it will aimed to evaluate the effect of magnesium sulfate and ketamine HCl added to local anesthetic on postoperative pain management in the ultrasound-guided erector spina plane (ESP) block in patients will undergo video-assisted thoracoscopic surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Cukurova University

Adana, 01330, Turkey (Türkiye)

About this study

Patients who will undergo lung resection with elective video-assisted thoracoscopic surgery will be included in the study. After routine monitoring, general anesthesia induction, and intubation with a double-lumen tube, patients who are placed in a lateral position will receive an ESP block at the T5 level, accompanied by ultrasonography, for postoperative analgesia.

For this purpose; Group I (control group) 0.5% bupivacaine 20 ml, Group II 0.5% bupivacaine 20 ml+150 mg MgSO4, Group III 0% ,5 bupivacaine 20 ml+2 mg/kg ketamine HCl will be administered. In all groups, the total volume will completed to 25 ml with 0.9% NaCl.

After surgery, hemodynamic values (heart rate, systolic and diastolic blood pressure), oxygen saturation, VAS scores (at rest and effort), Ramsey sedation score, patients satisfaction scores, PCA morphine consumption, additional analgesic requirements, and side effects will be recorded.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • lung resection with video-assisted thoracoscopy,
  • voluntarily agree to participate in the study,
  • over 18 years old,
  • ASA I-III

Exclusion criteria

  • ASA>III
  • Coagulation disorders or anticoagulant agent therapy,
  • Allergy or hypersensitivity to any drug to be will be used in the study,
  • Epilepsy,
  • High intracranial pressure,
  • Unwillingness to participate in the study
  • Inability to use the PCA device

Treatment and study plan

Bupivacain

Drug

Bupivacaine is a local anesthetic agent commonly used in ESP block.

Magnesium sulfate

Drug

Magnesium is an adjuvant agent that can be added to the local anesthetic agent to increase analgesic effectiveness..

Ketamine Hydrochloride

Drug

Ketamine Hydrochloride is an also adjuvant agent that can be added to the local anesthetic to increase analgesic effectiveness.

Primary outcomes

  1. pain scores

    Time frame: Change from baseline pain scores at 24 hours

    postoperative pain scores will recorded used Visual Analog Scale (VAS, 0= no pain, 10=worst pain)

  2. morphine consumption

    Time frame: Change from baseline morphine consumption at 24 hours

    At the end of the surgery, patients will allowed to use the patient controlled analgesia (PCA) device. The PCA will deliver bolus doses of morphine (0,02 mg/kg) every 10 minutes without a background infusion.

Secondary outcomes

  1. side effects

    Time frame: postoperative 24 hours

    All of patients will visited in the thoracic surgery ward after surgery and side effects (if occured) will recorded.

Sponsors and collaborators

Lead sponsor

Cukurova University

Other

Registry information

Official study title

Comparison of Analgesic Effects of Magnesium Sulphate and Ketamine Added to 0.5% Bupivacaine for Erector Spinae Plane Block in Patients Undergoing Video-assisted Thoracoscopic Surgery

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
May 11, 2023
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.